前传奇生物副总裁潘琦加盟水木分子，出任生物医药首席科学家

Core Insights - Pan Qi, former Vice President of Legend Biotech, has joined the AI biopharmaceutical company "Shuimu Molecule," incubated by Tsinghua University's Intelligent Industry Institute (AIR), as Chief Scientist responsible for biopharmaceutical and ChatDD research strategies, R&D system construction, AI drug pipeline advancement, and global collaboration [1][3][5] Group 1: Company Overview - Shuimu Molecule is an AI biopharmaceutical startup that integrates AI large models with biomedicine, founded by Zhang Yaqin and incubated by Tsinghua University's AIR [3][5] - The company is led by Professor Nie Zaiqing, who is the Chief Scientist and has a background in AI research at Alibaba [3][5] Group 2: Leadership Background - Pan Qi has over 20 years of experience in the biopharmaceutical field, covering target discovery, drug development, clinical translation, and strategic collaboration, with significant expertise in AI and drug development [3][5] - Prior to joining Shuimu Molecule, Pan Qi served as Senior Vice President of Cancer Biology at the AI oncology biotech company Pathos and was previously Vice President at Legend Biotech, where he built CAR-T and TCR-T cell therapy pipelines from scratch [3][5] - The DLL3 CAR-T project led to a global licensing collaboration between Legend Biotech and Novartis, with an upfront payment of $100 million [3][5]